Workflow
ETX
icon
Search documents
e-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 with Positive Non-clinical Data
Globenewswire· 2025-07-10 12:00
ETX-312 well tolerated at exaggerated dose levels in GLP-compliant toxicology studies GMP manufacturing of clinical trial batch successfully completed On track for CTA submission in Q4 2025 LONDON, July 10, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced significant progress on its lead candidate, ETX-312, a GalOmic siRNA therapy for the treatment of metabolic dysfunction-associated steat ...
禾赛科技系列三-一季报点评:一季度收入同比增长46%,激光雷达新产品、新客户持续突破【国信汽车】
车中旭霞· 2025-06-07 10:57
禾赛科技系列 车中旭霞 行业深度 《 汽车前瞻研究系列十六-激光雷达的市场空间、技术路线及产业链拆解 》——20220127 公司深度 《 禾赛科技(HSAI.O)-受益于激光雷达行业渗透率加速上行,技术及规模构建护城河》——20250415 公司点评 《禾赛科技(HSAI.O)-一季度收入同比增长46%,激光雷达新产品、新客户持续突破》-20250605 核心观点 2025Q1公司实现营业收入5.25亿元,同比增长46% 2025Q1,公司实现收入为5.25亿元,同比增长46.3%,环比减少27.0%,净利润为-0.18亿元(2024Q1为-1.07亿元, 2024Q4为1.47亿元),调整后净利润(即加回股权激励费用后的净利润)为860万元(2024Q1为-6910万元,2024Q4为 1.7亿元)。分业务来看,1)2025 Q1,公司产品收入为 5.1 亿元,同比增长 44.7%,环比减少27.2%,同比增长主要由 于中国需求旺盛导致 ADAS 激光雷达产品销售收入增加;2)2025Q1,公司服务收入为 1460 万元,同比增长 139.3%,环比减少19.8%,同比增长主要系非经常性工程服务收入的增加 ...
禾赛科技:收入符合指引,Non-GAAP同比扭亏为盈,两大业务稳健发展
Tianfeng Securities· 2025-06-07 10:20
禾赛科技 证券研究报告 2025 年 06 月 07 日 收入符合指引,Non-GAAP 同比扭亏为盈,两大业务 稳健发展 25Q1 业绩概览:收入符合指引,利润超预期。25Q1 收入 5.3 亿元, yoy+46.3%;毛利率 41.7%,yoy+2.9pcts;Non-GAAP 净利润 860 万元,同 比扭亏为盈。 海外行业报告 | 行业动态研究 作者 孔蓉 分析师 SAC 执业证书编号:S1110521020002 kongrong@tfzq.com 交付量方面,25Q1 激光雷达总出货量为 195818 台,yoy+231.3%,其中, ADAS 激光雷达出货量为 146087 台,yoy+178.5%。 业务进展:在全球范围内与 23 家 OEM 达成 ADAS 定点合作,涉及 120 多 种车型。 ADAS:海外方面,与一家总部位于日本的全球前五 Tier 1 达成了一项新的 POC 计划;推动与欧洲和日本的四家全球顶级 OEM 和 Tier 1 的五个 POC 项目,其中三个项目在 25Q1 完成。国内方面,近期新增多个车企的新车 型定点合作,包括奇瑞 iCAR、长城汽车欧拉、极氪多款畅销车型 ...
禾赛科技(A20721):一季度收入同比增长46%,激光雷达新产品、新客户持续突破
Guoxin Securities· 2025-06-05 11:40
Investment Rating - The investment rating for the company is "Outperform the Market" [6][4][33] Core Insights - The company achieved a revenue of 525 million yuan in Q1 2025, representing a year-on-year growth of 46.3% [7][4] - The gross margin improved to 41.7%, with a year-on-year increase of 3.0 percentage points, driven by effective cost control and scale optimization in the ADAS and robotics sectors [3][11] - The company launched new laser radar products, including the AT1440, ETX, and FTX, enhancing its product offerings for L2 to L4 autonomous driving applications [21][22] - The company has established partnerships with over 23 domestic and international automotive manufacturers, securing production agreements for more than 120 vehicle models [26][28] Financial Performance - In Q1 2025, product revenue was 510 million yuan, up 44.7% year-on-year, primarily due to strong demand for ADAS laser radar products in China [7][4] - Service revenue reached 14.6 million yuan, a significant increase of 139.3% year-on-year, attributed to non-recurring engineering service income [7][4] - The company forecasts revenues of 3.138 billion yuan, 4.347 billion yuan, and 6.037 billion yuan for 2025, 2026, and 2027, respectively, with corresponding net profits of 221 million yuan, 498 million yuan, and 868 million yuan [5][33] Market Position and Strategy - The company is a leading supplier of laser radar for Robotaxi services, collaborating with major players like Baidu Apollo Go and Didi Autonomous Driving [28][32] - The company signed a strategic cooperation agreement to supply 300,000 JT series laser radars to a high-end smart garden brand, indicating its expanding presence in the robotics market [32][4] - The company is actively pursuing international partnerships, including a new verification development project with a top-tier automotive supplier in Japan, enhancing its global footprint [25][4]
禾赛科技(A20721):2025年一季报点评:产品切换顺利上量,看好智驾与泛机器人双擎增长
Soochow Securities· 2025-05-29 13:36
证券研究报告·海外公司点评·光学光电子 禾赛科技(HSAI) 2025 年一季报点评:产品切换顺利上量,看 好智驾与泛机器人双擎增长 买入(维持) | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入(百万美元) | 265.01 | 288.96 | 474.27 | 643.77 | 847.83 | | 同比(%) | 53.47 | 9.04 | 64.13 | 35.74 | 31.70 | | 归母净利润(百万美元) | (67.20) | (14.24) | 33.91 | 73.86 | 121.53 | | 同比(%) | (55.61) | 78.81 | 338.10 | 117.80 | 64.55 | | EPS-最新摊薄(美元/股) | (0.51) | (0.11) | 0.26 | 0.56 | 0.93 | | P/E(现价&最新摊薄) | (40.64) | (191.74) | 80.53 | 36.97 | ...
禾赛Q1营收同比增46%、实现Non-GAAP盈利:单季交付近20万台激光雷达
IPO早知道· 2025-05-27 01:29
预计全年营收同比增长44%至69%。 本文为IPO早知道原创 作者| Stone Jin 微信公众号|ipozaozhidao 据 IPO早知道消息, 禾赛科技( NASDAQ:HSAI) 于 5月27日 公布了 2025年第一季度未经审计的 财务数据。 财报显示, 禾赛 第一季度实现营收 5.3亿元人民币,同比增长46.3%,预计全年营收同比将增长 44%至69%。同时,禾赛实现GAAP净亏损同比大幅收窄84%至1750万元人民币(约合240万美 元),并实现Non-GAAP盈利,稳步迈向全年盈利目标 ; Robotaxi与ADAS业务的综合毛利率 则 为 41.7% 。 第一季度中, 禾赛激光雷达总交付量 195,818台,同比增长231.3%,是2024年第一季度的三倍以 上。其中,ADAS产品交付量为146,087台,同比增长178.5 %; 在机器人领域交付量为 49,731 台,同比增长649.1% 。 禾赛联合创始人及 CEO李一帆表示 : "根据Yole Group最新数据,禾赛已经连续第四年蝉联全球车 载激光雷达营收市占率第一,这进一步巩固了禾赛在行业中的领导地位。2025年开局强劲,我们将 ...
Hesai Group Reports First Quarter 2025 Unaudited Financial Results
GlobeNewswire News Room· 2025-05-26 21:00
Core Insights - Hesai Group reported strong financial results for Q1 2025, with net revenues of RMB525.3 million (US$72.4 million), a 46.3% increase year-over-year [17][31] - The company shipped 195,818 lidar units in Q1 2025, representing a 231.3% increase from the same period in 2024 [16][15] - Hesai was ranked as the world's No.1 automotive lidar company by revenue market share for the fourth consecutive year in 2024 [3] Financial Performance - Net revenues for Q1 2025 were RMB525.3 million, up from RMB359.1 million in Q1 2024, driven by increased sales of ADAS lidar products [17][31] - Gross margin improved to 41.7% in Q1 2025 from 38.8% in Q1 2024, attributed to effective cost and scale optimization [17][31] - The net loss narrowed significantly by 83.6% year-over-year to RMB17.5 million (US$2.4 million) [22][31] Operational Highlights - ADAS lidar shipments reached 146,087 units in Q1 2025, a 178.5% increase from 52,462 units in Q1 2024 [16][15] - The company secured new design wins with 23 OEMs globally across over 120 vehicle models, including partnerships with Chery, Great Wall Motor, Zeekr, and Geely [5][15] - Hesai is the main lidar supplier for next-generation Robotaxi fleets from Baidu Apollo Go, DiDi, Pony.ai, and WeRide [14][15] Product Development - New products include the AT1440 lidar, which delivers ultra-high-definition point clouds, and the FTX solid-state lidar for blind spot detection [14] - The company announced the successful resolution of all IP-related litigation against it, reinforcing its commitment to innovation and R&D [8][10] Business Outlook - For Q2 2025, Hesai expects net revenues to be between RMB680 million (US$93.7 million) and RMB720 million (US$99.2 million), indicating a year-over-year increase of approximately 48% to 57% [19]
对话禾赛科技CEO李一帆:禾赛没有一天选择过代工
Group 1 - The trend of intelligent driving is leading to more advanced features being integrated into lower-priced vehicles, with safety becoming a critical focus [1] - The "LiDAR" technology is now available in vehicles priced around 120,000 yuan, exemplified by the Leapmotor B10, which utilizes Hesai's ATX [1] - Hesai Technology launched the "Thousand Eyes" perception solution for L2 to L4 level intelligent driving, offering three different combinations tailored for mainstream L2 level auxiliary driving systems [1] Group 2 - Hesai also introduced a series of automotive-grade LiDAR products, including ETX ultra-long-range LiDAR, AT1440 ultra-high-definition LiDAR, and FTX pure solid-state blind-spot LiDAR [1] - Hesai is recognized as the leading player in the domestic LiDAR industry, with major clients including Li Auto, Xiaomi Auto, and BYD, with Li Auto equipping all its models with Hesai's LiDAR this year [1] - On the international front, Hesai announced a significant long-term exclusive partnership with a top European OEM, marking the largest order in the overseas front-end production LiDAR sector to date [2]
e-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH
Globenewswire· 2025-05-07 13:00
LONDON, May 07, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced it will present new preclinical results on its GalOmic small‑interfering RNA (siRNA) candidate ETX‑312 for the treatment of metabolic dysfunction‑associated steatohepatitis (MASH) at the European Association for the Study of the Liver (EASL) Congress, 7-10 May 2025. In the leading Gubra‑Amylin NASH diet‑induced obese (GAN‑DIO ...
迈瑞医疗(300760) - 2025年4月29日投资者关系活动记录表
2025-04-29 01:16
Financial Performance - In 2024, the company achieved total revenue of 36.726 billion CNY, a year-on-year increase of 5.14% [2] - The net profit attributable to shareholders was 11.668 billion CNY, up 0.74% year-on-year; excluding financial expenses, the net profit growth was 4.36% [2] - Operating cash flow reached 12.432 billion CNY, reflecting a year-on-year increase of 12.38% [2] - For Q1 2025, total revenue was 8.237 billion CNY, a decline of 12.12% compared to the same period last year, with net profit down 16.81% [9] Dividend Distribution - The company plans to distribute 679 million CNY (including tax) as dividends for 2024, with a cumulative cash dividend of 7.602 billion CNY, representing a payout ratio of 65.15% [3] - A proposal for a mid-year dividend of 1.71 billion CNY (including tax) for 2025 is also in place, pending shareholder approval [3] Market Performance International Market - The international market grew by 21.28% in 2024, with the Asia-Pacific region seeing nearly 40% growth driven by countries like Australia, Thailand, and India [4] - International revenue accounted for approximately 45% of total revenue, with high-potential segments like minimally invasive surgery and cardiovascular care nearing 10% of international income [4] Domestic Market - The domestic market experienced a decline of 5.10% due to sluggish hospital equipment procurement and the impact of DRG 2.0 [4] - A recovery is anticipated in Q3 2025 as local fiscal pressures ease and medical equipment projects are initiated [4] Product Line Performance In Vitro Diagnostics (IVD) - The IVD segment grew by 10.82% in 2024, with international IVD growth exceeding 30% [5] - IVD revenue now constitutes 37.48% of total company revenue, surpassing the life information and support segment [5] Medical Imaging - The medical imaging segment grew by 6.60%, with international growth over 15% [7] - The launch of the high-end Resona A20 ultrasound is expected to enhance market presence [7] Life Information and Support - This segment saw a decline of 11.11%, although international growth was in double digits [8] - The company maintains a leading market share in domestic monitoring and respiratory devices despite challenges [8] Research and Development - R&D investment for 2024 was 4.008 billion CNY, accounting for 10.91% of revenue, while Q1 2025 saw 847 million CNY in R&D, representing 10.28% of revenue [11] - New product launches include advanced systems in life information and support, IVD, and medical imaging [12][13] Sustainability Efforts - The company received an AA rating from MSCI ESG and was included in the S&P Global Sustainable Development Yearbook [14] - Carbon emissions intensity decreased by 11.6% compared to 2021, with ongoing projects contributing to sustainability goals [15] Future Outlook - The company anticipates a significant recovery in domestic revenue starting Q3 2025, driven by the resumption of medical equipment projects [10] - Long-term growth strategies focus on digitalization, internationalization, and enhancing the supply chain to adapt to changing market conditions [24][25]